ESGVS: Sclerotherapy With Lauromacrogol
Venous Insufficiency, Saphenous Vein
About this trial
This is an interventional treatment trial for Venous Insufficiency focused on measuring lauromacrogol, Sclerotherapy
Eligibility Criteria
Inclusion Criteria: 25 - 75 years Hawaii CEAP classification : C2-5 Ep, As2-3 Pr Clinical Varicose veins C2, Edema C3, Skin changes C4, Healed ulcer C5 Etiology Ep Primary GSV insufficiency As2-3: Ostial and or crural truncular GVS incompetence Maximal inferior diameter of the leg GSV (patient in decubitus) between 4 and 8mm Pr: reflux by echo doppler in orthostatism > 1 second Information consent form signed by the investigator and the patient. Exclusion Criteria: deep venous reflux (CEAP: Ad) Short saphenous vein or non saphenous network insufficiency (CEAP: A4-5) Clinical class: C1 or C6 Recurrent GSV varicose veins after stripping Thrombophilia or antecedent of deep vein thrombosis Psychiatric disorders Known allergy to Lauromacrogol or to one of its component Arteriopathy. (IPS < 0.8) Post-thrombotic disease Chronic hepatoma Renal insufficiency (creatinine > 150 micromol/l)
Sites / Locations
- Center of Vascular Medecine - 7 rue Lesdiguières